
Nkarta Inc (NASDAQ:NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dose finding studies.
The positive data was for the company's two lead chimeric antigen receptor natural killer cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies.